62165

🩺 CPT 62165 — Neuroendoscopy, Intracranial; with Excision of Pituitary Tumor, Transnasal or Transsphenoidal Approach

Code Description

CPT 62165 describes a fully endoscopic, intracranial neurosurgical procedure in which a small neuroendoscope is introduced through the nasal cavity or the sphenoidal sinuses to access and excise a tumor of the pituitary gland. This is a single-code bundled service that includes all three operative components: the endonasal approach, the tumor resection itself, and closure of the operative field. There is no separate CPT code for any of these components when performed as part of the endoscopic transsphenoidal pituitary resection — they are all considered integral to 62165.

This code was introduced in 2003, approximately nine years after the open-approach pituitary resection codes were established, reflecting the lag between clinical adoption of endoscopic technique and CPT code development. Before 2003, surgeons performing endoscopic endonasal pituitary resection had no specific code and were forced to use unlisted procedure codes, making reimbursement highly variable and difficult.

62165 is specifically restricted to pituitary tumors accessed via this approach. It is not appropriate for other skull base lesions or non-pituitary neoplasms reached through the endonasal corridor — those procedures require unlisted codes (e.g., 64999 for nervous system, 31299 for accessory sinuses).

Anatomy and Procedural Overview

The pituitary gland (hypophysis) sits within the sella turcica, a bony saddle-shaped depression in the sphenoid bone at the base of the skull. It is a small but vital endocrine organ (~1 cm in diameter) consisting of the anterior lobe (adenohypophysis) and the posterior lobe (neurohypophysis), and it regulates growth hormone, prolactin, ACTH, TSH, FSH, LH, and ADH secretion.

Pituitary tumors (most commonly adenomas) are classified by size and function. Microadenomas are less than 10 mm; macroadenomas are 10 mm or greater. Functioning adenomas hypersecrete specific hormones (growth hormone in acromegaly, prolactin in prolactinoma, ACTH in Cushing’s disease), while non-functioning adenomas cause mass effect — most notably compression of the optic chiasm, causing bitemporal hemianopsia.

The transsphenoidal endoscopic approach involves introducing the endoscope through one or both nares, traversing the posterior nasal cavity, entering the sphenoid sinus via the sphenoid ostia or posterior septum, opening the anterior sphenoid face, and accessing the sella. The sella floor is opened with a drill or curette, the dura is incised, and the tumor is removed with curettes and suction. The surgical corridor is narrow and precise, with the optic chiasm and cavernous sinuses (harboring cranial nerves III, IV, V1, V2, and VI, as well as the internal carotid artery) as critical nearby structures.

CPT Code Details

Field	Detail
CPT Code	62165
Full Description	Neuroendoscopy, intracranial; with excision of pituitary tumor, transnasal or transsphenoidal approach
Code Family	Neuroendoscopy Procedures on the Skull, Meninges, and Brain
Introduced	2003
Surgical Approach	Endoscopic endonasal (transnasal or transsphenoidal)
Global Period	090 (Major surgery — 1 day pre-op, day of surgery, 90 days post-op)
Facility Only	Yes — performed in hospital OR or ASC; not office-based
wRVU	~30.29
Assistant Payable	Yes
Co-Surgery (Mod 62)	Yes — standard for ENT/Neurosurgery co-surgical teams
Bilateral Indicator	N/A
Add-On Code	No

Work RVU (wRVU) and Reimbursement

CPT 62165 carries a work RVU of approximately 30.29, reflecting the significant technical skill, intraoperative decision-making, and time commitment required for this intracranial endoscopic procedure. The total RVU (including practice expense and malpractice) is higher. Using the 2025 Medicare conversion factor of $32.3465, the professional component reimbursement approximates several hundred dollars per surgeon — though the actual dollar amount varies significantly by geographic GPCI adjustment and payer contract.

Because this is classified as a major surgery with a 90-day global period, the surgical payment bundle includes:

The preoperative evaluation on the day before surgery
The intraoperative service itself
All routine postoperative follow-up for 90 consecutive days

Separate billing for routine post-op E/M visits within this window is not permitted unless the visit is for a condition unrelated to the pituitary surgery.

Co-Surgery with Modifier 62

When both an otolaryngologist (ENT) and a neurosurgeon participate as co-surgeons — which is the predominant practice pattern — each surgeon appends Modifier 62 to 62165. In this arrangement, the ENT typically performs the endonasal approach (the sphenoidotomy and sellar exposure) while the neurosurgeon performs the tumor resection. Since neither surgeon alone performs the complete global service, each reports 62165-62. Medicare and most payers allow 62.5% of the full allowed amount to each co-surgeon, resulting in a combined payment of 125% of the single-surgeon rate. Both surgeons are subject to the full 90-day global period and must maintain detailed individual operative notes clearly delineating their respective work, while referencing the co-surgeon’s note for the portions they did not personally perform.

A neurosurgeon performing the entire procedure solo (without ENT co-surgeon involvement) reports 62165 without Modifier 62.

Assistant Surgeon (Modifier 80)

A separately billing assistant surgeon using Modifier 80 is payable for 62165. The assistant surgeon receives approximately 16% of the allowed amount. This would apply when a resident or fellow cannot be the billing assistant and a qualified physician assistant or second attending serves as assistant. Modifier 82 (assistant surgeon when qualified resident unavailable) is used in teaching facilities under appropriate circumstances.

What Is Included in 62165

The following services are bundled into 62165 and cannot be separately billed:

Endonasal approach and sphenoidotomy
Intraoperative neuroendoscopy and visualization
Sellar floor drilling/removal
Dural opening
Pituitary tumor resection (by suction, curette, or ring curette)
Intraoperative hemostasis
Primary closure of the dura and sellar floor with autologous fat, fascia, or synthetic material (when performed through the same incision/corridor without a separate skin incision)
Routine closure of the sphenoid sinus and nasal corridor

What Is NOT Included (Separately Reportable)

The following may be reported separately when clearly documented and medically necessary:

Abdominal fat graft harvest (20926) — If a separate abdominal incision is made to harvest fat for skull base closure, this may be reported in addition to 62165
Lumbar drain placement (62272) — If a lumbar drain is placed separately to manage or prevent CSF leak, this is separately reportable
Neuronavigation/stereotactic navigation (+61781 or +61782) — Add-on codes for frameless stereotactic guidance used in conjunction with the primary procedure
Operating microscope (+69990) — If microsurgical technique with the operating microscope is separately and distinctly documented in addition to the endoscope (controversial; document carefully)
Fluoroscopy (77002) — Separately reportable in some scenarios per CPT guidelines, though payer policy varies
Dura repair codes (61618, 61619) — Rarely needed given modern primary closure techniques, but available for complex dural reconstruction

Modifier 22 may be appended to 62165 when the procedure is substantially more complex than typical — for example, with significant cavernous sinus invasion, prior surgery creating dense adhesions, or giant macroadenoma with suprasellar extension and difficult exposure. Documentation must clearly support the substantially increased work, time, and technical difficulty.

Excludes / Do Not Report With

61548 (Hypophysectomy or excision of pituitary tumor, transnasal or transseptal approach, nonstereotactic) — This is the open/microscopic (non-endoscopic) approach code. Do not report 61548 with 62165; they describe alternative techniques for the same procedure via the same corridor.
31299 (Unlisted procedure, accessory sinuses) — Should not be billed in addition to 62165 for the sphenoidotomy when it is part of the approach; bundled into 62165
31288 / 31259 — Endoscopic sinus procedures are bundled when performed as part of the transsphenoidal approach
30520 (Septoplasty) — Included when septal work is performed solely to gain access; separately reportable only if performed for an independent indication with separate documentation

MS-DRG Assignment

When CPT 62165 is performed in the inpatient hospital setting, the MS-DRG assignment is driven by the principal ICD-10-CM/PCS diagnosis code and the presence of MCC/CC complicating conditions. The operative ICD-10-PCS procedure codes assigned by the facility coder (not the CPT code) drive DRG logic.

The most common DRG assignments associated with pituitary surgery include:

MS-DRG	Title	Notes
025	Craniotomy and Endovascular Intracranial Procedures with MCC	Highest severity, highest reimbursement weight
026	Craniotomy and Endovascular Intracranial Procedures with CC	Intermediate
027	Craniotomy and Endovascular Intracranial Procedures without CC/MCC	Base DRG, lowest weight in this family
643	Endocrine Disorders with MCC	May apply when surgery is not the OR procedure or when case is primarily medical
644	Endocrine Disorders with CC	Same caveat
645	Endocrine Disorders without CC/MCC	Base endocrine DRG

For most inpatient pituitary adenoma resections, MS-DRG 025/026/027 is appropriate because the ICD-10-PCS OR procedure (endoscopic approach, resection, pituitary gland) triggers the craniotomy MDC grouping. CC/MCC capture is critical for appropriate DRG weight — be thorough in querying and documenting comorbidities such as hyponatremia, hypopituitarism, vision loss, diabetes insipidus, and CSF leak.

ICD-10-CM Diagnosis Codes

Principal Diagnosis (most common)

ICD-10-CM	Description	Notes
D35.2	Benign neoplasm of pituitary gland	Most common — covers pituitary adenomas (non-functioning and functioning), macroadenomas, microadenomas; confirmed benign by pathology
C75.1	Malignant neoplasm of pituitary gland	Pituitary carcinoma (rare); requires pathologic confirmation of malignancy
D44.3	Neoplasm of uncertain behavior of pituitary gland	Use when behavior is indeterminate prior to or without definitive pathology
E22.0	Acromegaly and pituitary gigantism	GH-secreting adenoma; may be used as principal or secondary depending on presentation
E22.1	Hyperprolactinemia	Prolactinoma; often medical management first, surgical when refractory
E24.0	Pituitary-dependent Cushing’s disease	ACTH-secreting corticotroph adenoma

Common Secondary / Comorbid Diagnoses

ICD-10-CM	Description	Notes
E23.0	Hypopituitarism	Mass effect causing pituitary insufficiency
H53.46	Quadrant visual field defects	Bitemporal hemianopsia from optic chiasm compression — important MCC/CC consideration
G97.0	Intracranial hypotension following lumbar puncture	If lumbar drain used postoperatively
G97.81	Other intraoperative complications of nervous system	Intraoperative CSF leak
G97.82	Other postprocedural complications of nervous system	Postoperative CSF leak
E23.2	Diabetes insipidus	Postoperative complication from posterior pituitary/stalk disruption — an important CC capture
E87.1	Hyponatremia	SIADH following pituitary surgery — important CC
E27.49	Other adrenocortical insufficiency	Adrenal insufficiency from ACTH deficiency
Z79.51	Long-term use of inhaled steroids	Relevant for Cushing’s patients
R41.3	Other amnesia	Cognitive changes related to tumor

HCC (Hierarchical Condition Category) Relevance

While CPT 62165 is a procedure code and not directly mapped to an HCC, the associated diagnosis codes carry significant HCC implications for risk-adjustment purposes (relevant for Medicare Advantage and quality programs).

ICD-10-CM	HCC Mapping	Notes
C75.1	HCC 10 — Lymphatic and Solid Tumor with Major Complications (or similar oncology HCC)	Malignant pituitary neoplasm — high risk score
D44.3	HCC 12 — Breast, Prostate, Colorectal and Other Cancers and Tumors (uncertain behavior neoplasms may qualify)	Verify current CMS HCC model mapping annually
E24.0 (Cushing’s)	HCC 23 — Other Significant Endocrine and Metabolic Disorders	Cushing’s disease from pituitary source
E22.0 (Acromegaly)	HCC 23	Same endocrine HCC category
E23.0 (Hypopituitarism)	HCC 23	Endocrine disorder HCC
E23.2 (Diabetes insipidus)	HCC 23	Documented postoperative DI captures an endocrine HCC
H53.46 (Visual field defect)	HCC 124 — Exudative Macular Degeneration / Vision — confirm current year mapping	Bitemporal hemianopsia from chiasm compression

HCC capture is most impactful for Medicare Advantage risk-adjusted revenue. All active, documented, and clinically managed diagnoses at the time of the encounter should be coded. A pituitary adenoma patient on hormone replacement therapy, with documented visual field defects and postoperative DI, can generate multiple HCCs from a single surgical encounter.

Pituitary Surgery — Open/Microscopic Alternatives

Pituitary Tumor Resection
├── Endoscopic Endonasal (transsphenoidal)
│   └── 62165 — Neuroendoscopy, intracranial; excision pituitary tumor, transnasal or transsphenoidal
│
├── Open / Microscopic Transsphenoidal
│   └── 61548 — Hypophysectomy or excision of pituitary tumor, transnasal or transseptal, nonstereotactic
│
├── Craniotomy Approaches (non-transsphenoidal)
│   ├── 61510 — Craniectomy, trephination, bone flap craniotomy; for excision of brain tumor (supratentorial)
│   └── 61518 — Craniectomy for excision of brain tumor, infratentorial or posterior fossa
│
└── Radiosurgery
    ├── 61790 — Stereotactic radiosurgery; one simple cranial lesion
    └── 61791 — Stereotactic radiosurgery; one complex cranial lesion

Neuroendoscopy Family (62160-62165)
├── 62160 — Neuroendoscopy, intracranial; with placement of ventricular catheter
├── 62161 — Neuroendoscopy, intracranial; with dissection of adhesions, fenestration of septa, etc.
├── 62162 — Neuroendoscopy, intracranial; with fenestration of intraventricular cysts/septum pellucidum
├── 62163 — Neuroendoscopy, intracranial; with retrieval of foreign body
├── 62164 — Neuroendoscopy, intracranial; with excision of brain tumor, including meningioma
└── 62165 — Neuroendoscopy, intracranial; with excision of pituitary tumor, transnasal or transsphenoidal ← THIS CODE

Add-On Codes Commonly Reported with 62165

Code	Description
+61781	Stereotactic computer-assisted volumetric (navigational) procedure, cranial (add-on)
+61782	Stereotactic computer-assisted volumetric procedure, spinal/cranial nerve (add-on)
+69990	Operating microscope use (add-on) — use with caution; document need distinctly from endoscope
20926	Tissue graft, other (fat graft harvest) — separately reportable with separate skin incision only
62272	Spinal puncture, therapeutic; for drainage of CSF — lumbar drain, separately reportable

Modifiers

Modifier	Use with 62165	Notes
-62	Co-surgery	Standard for ENT + Neurosurgery co-surgeon teams; each surgeon gets ~62.5% of allowed amount
-22	Increased procedural services	Cavernous sinus invasion, prior surgery with adhesions, giant macroadenoma — requires detailed documentation
-51	Multiple procedures	Reduced payment for additional procedures on same day; not applied to 62165 itself as primary
-57	Decision for surgery	Appended to E/M the day before or day of surgery when decision to operate was made at that visit
-54	Surgical care only	When one surgeon performs surgery and another assumes all post-op care
-55	Postoperative management only	Receiving surgeon’s modifier
-78	Unplanned return to OR for related procedure during post-op period	e.g., re-exploration for CSF leak repair, hematoma evacuation
-79	Unrelated procedure during post-op period	Separately payable
-80	Assistant surgeon	Separately billing assistant; receives ~16% of allowed amount
-82	Assistant surgeon (no qualified resident available)	Teaching facility use

Coding Examples

Example 1 — Standard Pituitary Macroadenoma, Single Neurosurgeon

A 44-year-old male presents with progressively worsening bitemporal hemianopsia and headaches. MRI demonstrates a 2.2 cm pituitary macroadenoma with suprasellar extension and optic chiasm compression. A neurosurgeon performs the complete endoscopic endonasal transsphenoidal resection without ENT assistance. Neuronavigation was utilized.

Physician Billing (Neurosurgeon):

62165 — Endoscopic pituitary tumor excision
+61781 — Neuronavigation (add-on)

Diagnosis Codes:

D35.2 — Benign neoplasm of pituitary gland (principal)
H53.46 — Quadrant visual field defects (bitemporal hemianopsia; also captures as CC for DRG)

Facility (Inpatient) ICD-10-PCS Example:

Principal Dx: D35.2
Procedure: 00B00ZZ — Excision of Brain, Open Approach (facility coders use PCS, not CPT)

Example 2 — Co-Surgery with ENT and Neurosurgery, Modifier 62

A 38-year-old female with acromegaly confirmed by IGF-1 levels and GH hypersecretion on MRI shows a 1.6 cm right-sided pituitary adenoma. Otolaryngology performs the endonasal approach and sphenoidotomy; neurosurgery performs the sella entry and adenoma resection under shared OR team management.

ENT Physician Billing:

62165-62 — Co-surgeon, endoscopic pituitary excision

Neurosurgeon Physician Billing:

62165-62 — Co-surgeon, endoscopic pituitary excision

Diagnosis Codes (both surgeons):

E22.0 — Acromegaly and pituitary gigantism (principal)
D35.2 — Benign neoplasm of pituitary gland (additional)

Example 3 — Cushing’s Disease, Complex Case with Modifier 22 and Fat Graft

A 52-year-old female with ACTH-dependent Cushing’s disease undergoes endoscopic transsphenoidal resection of a 6 mm corticotroph microadenoma. Intraoperative high-definition endoscopy reveals significant fibrous adhesion from prior surgery and cavernous sinus involvement requiring careful dissection over 6+ hours. An abdominal fat graft is harvested through a separate infraumbilical incision for sellar floor reconstruction.

Physician Billing:

62165-22 — Significantly increased procedural complexity (prior surgery, cavernous sinus invasion, extended operative time)
20926 — Tissue graft, other (abdominal fat graft harvest through separate incision)

Diagnosis Codes:

E24.0 — Pituitary-dependent Cushing’s disease (principal)
D35.2 — Benign neoplasm of pituitary gland
E27.49 — Other adrenocortical insufficiency (secondary)

Documentation Required for Modifier 22: Operative note must clearly describe the additional complexity — prior surgical adhesions, cavernous sinus involvement, operative time substantially exceeding typical, additional instruments or maneuvers required.

Example 4 — Postoperative Diabetes Insipidus (Complication Coding)

Following uncomplicated endoscopic pituitary resection for a D35.2 macroadenoma, the patient develops polyuria and polydipsia on POD 1. Serum sodium is 149 with low urine osmolality. Endocrinology confirms central diabetes insipidus from posterior pituitary/stalk disruption. DDAVP is initiated.

Additional ICD-10-CM codes for the admission (facility coding):

E23.2 — Diabetes insipidus (postoperative complication — this is a CC and will impact DRG weight)
G97.82 — Other postprocedural complications of nervous system

DRG Impact: The capture of E23.2 as a CC may move the DRG from 027 (without CC/MCC) to 026 (with CC), representing a meaningful increase in facility reimbursement weight.

Documentation Tips for Inpatient Coders

Always confirm whether the pituitary tumor is benign (D35.2), malignant (C75.1), or uncertain behavior (D44.3) from pathology report, not just operative impression
Query for diabetes insipidus (E23.2) when postoperative urine output is high and DDAVP is initiated — this is a frequent CC that improves DRG weight
Query for hyponatremia/SIADH (E87.1 + E22.2 if SIADH) when sodium drops postoperatively — also a potential CC
Document and code visual field defects (H53.46) when present preoperatively — improves risk capture and may impact DRG
Pituitary apoplexy — sudden hemorrhage into the tumor causing acute headache, vision loss, and pituitary failure — should be coded as I60.8 (other nontraumatic subarachnoid hemorrhage) or D35.2 with apoplexy noted, and queried for specificity
The operative approach (endoscopic endonasal transsphenoidal) must be clearly documented in the operative report to support 62165 versus 61548 (open/microscopic approach)
When Modifier 62 is used, both surgeons must have separate, signed operative notes identifying their individual contributions; conflicting information between notes is a significant audit risk

Payer and Compliance Considerations

NCCI Edits: Review NCCI Procedure-to-Procedure (PTP) edits before billing any additional codes on the same date as 62165. Many sinus and skull base procedure codes are bundled with 62165 when performed for the approach.
Unlisted Codes for Non-Pituitary Skull Base: 62165 is restricted strictly to pituitary tumors. Extended endonasal approaches for craniopharyngiomas, chordomas, meningiomas, or other skull base lesions require unlisted codes (64999, 31299, etc.) and comparison to the closest analogous code for reimbursement negotiation.
Medicare Global Period: The 90-day global period for 62165 applies to all Medicare and most commercial payers. Post-op visits within 90 days by the operating surgeon for wound care, CSF leak management, or hormone follow-up related to the surgery are included in the global fee. Separate billing requires Modifier 24 (unrelated E/M during global) or Modifier 79 (unrelated procedure).
Teaching Hospital Billing: When 62165 is performed with co-surgery modifier 62 and a resident is involved, attending documentation must meet the teaching physician documentation requirements (key portion present and documented) for both the ENT and neurosurgeon components.

Explorer